MONROVIA, Calif. — Cell Care Therapeutics, Inc., a biotechnology company whose mission is to advance stem-cell derived therapies in ophthalmology, today announced the closing of a $4.3 million seed round investment from a syndicate of individual investors. This round of funding will be used to develop Cell Care’s manufacturing platform and to advance its lead preclinical-stage drug candidate for major eye diseases, including diabetic retinopathy (DR) and neovascular age-related macular degeneration (wet AMD), two of the leading causes of vision loss and blindness in the developed world. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Sistemic & Cynata sign Global Service & License Agreement for the use of SistemPSCCheck™
Glasgow, United Kingdom; 22nd October 2018: Sistemic Ltd. is pleased to announce the completion of a Global Service and License Agreement for its SistemPSCCheck™ assay with Australian stem cell and regenerative medicine company, Cynata Therapeutics Ltd. The agreement will see the use of the SistemPSCCheck™ assay for the assessment of residual pluripotent stem cells in Cynata’s current iPSC-derived MSC clinical candidate CYP-001, as well other planned iPSC-derived MSC products.
SistemPSCCheck™ is a first-in-class miRNA-based assay for high sensitivity assessment of residual pluripotent stem cells (PSCs) in derived cell preparations. It has been specifically designed to offer high levels of safety for characterisation and batch release testing to support the clinical and commercial development of PSC cell-derived cell therapy products. [Read more…]
CHAMP Private Equity Acquires Cell Care, Australia’s Largest Cord Blood Bank
CHAMP Private Equity is acquiring Cell Care, the largest cord blood bank within Australia, according to news released October 10, 2018, by the Australian Financial Review (AFR). According to AFR, “It is understood CHAMP will take a controlling stake in the business, while some of the vending shareholders will retain a minority shareholding.”
The transaction has important implications for the global stem cell banking marketplace, because the AFR estimates the deal to have a price tag of more than $100 million.
With this price tag, Cell Care will be well capitalized to continue its research into therapeutic applications of cord blood and tissue stem cells and may be positioned to expand into new markets beyond Australia and Canada.
[Read more…]
L7 Informatics Releases L7 Enterprise Science Platform 2.0 with Pre-Built Microsoft Genomics Integration
L7 ESP v.2.0 expands platform functionality to support complex “bench-to-bedside” life science industry and regulatory requirements
AUSTIN, Texas, Oct. 10, 2018 — L7 Informatics, Inc., formerly Lab7 Systems, a leader in informatics solutions and services for data intensive scientific applications and personalized medicine, is pleased to announce today the release of Enterprise Science Platform 2.0 (ESP) with a validated pre-built Microsoft Azure connector to the Microsoft Genomics service on the Azure cloud. [Read more…]
UniCAR Therapy and Terumo BCT Collaborate to Advance CAR T-Cell Therapies and Create a Shanghai, China Center of Excellence
LAKEWOOD, Colo., Oct. 09, 2018 — Shanghai UniCAR-Therapy Bio-Medicine Technology Co. chose Terumo BCT and its cell expansion devices to automate its cell therapy manufacturing process for chimeric antigen receptor (CAR) T-cell therapies. Privately held, UniCAR will open their Center of Excellence for Terumo BCT’s technologies in Shanghai in November.
Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular therapy technologies. The company provides flexible solutions for CAR T-cell developers and manufacturers, including the Quantum® Cell Expansion System, in use at UniCAR today. [Read more…]
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 123
- Next Page »